Abstract

JACC

Lots of interesting abstracts and cases were submitted for TCTAP 2022. Below are the accepted ones after a thorough review by our official reviewers. Don’t miss the opportunity to expand your knowledge and interact with authors as well as virtual participants by sharing your opinion in the comment section!

TCTAP A-012

First Report On 30-Day Outcomes of Patients Treated With DynamX Bioadaptor Drug-eluting Stent in Primary Percutaneous Coronary Intervention

By Hee Hwa Ho, Ki Fung Cliff Li, Jun Bang Low, Thet Khaing, Jinhyun Lee, Deanna Zin Lin Khoo, Jason Kwok Kong Loh, Fahim Haider Jafary

Presenter

Hee Hwa Ho

Authors

Hee Hwa Ho1, Ki Fung Cliff Li1, Jun Bang Low1, Thet Khaing1, Jinhyun Lee1, Deanna Zin Lin Khoo1, Jason Kwok Kong Loh1, Fahim Haider Jafary1

Affiliation

Tan Tock Seng Hospital, Singapore1
View Study Report
TCTAP A-012
Acute Coronary Syndromes (STEMI, NSTE-ACS)

First Report On 30-Day Outcomes of Patients Treated With DynamX Bioadaptor Drug-eluting Stent in Primary Percutaneous Coronary Intervention

Hee Hwa Ho1, Ki Fung Cliff Li1, Jun Bang Low1, Thet Khaing1, Jinhyun Lee1, Deanna Zin Lin Khoo1, Jason Kwok Kong Loh1, Fahim Haider Jafary1

Tan Tock Seng Hospital, Singapore1

Background

The DynamX Bioadaptor drug-eluting stent (DES) is a new class of treatment for coronary artery disease with the unique property of adapting to vessel physiology. It has the potential to allow the vessel to expand with restoration of vasomotion resulting in better clinical outcomes. There is limited data on the outcomes of DynamX Bioadaptor DES in the setting of primary percutaneous coronary intervention (PPCI). We evaluated the clinical efficacy and safety of DynamX Bioadaptor DES in PPCI and report on the 30-day clinical outcomes.  

Methods

Between January 2021 to October 2021, 20 patients ( 80% male, mean age 57.7 ± 11.2 years) were treated with DynamX Bioadaptor DES during PPCI.  The primary endpoint was major adverse cardiac events (MACE) ie a composite of all-cause mortality, reinfarction and and target lesion revascularization (TLR) within 30 days of follow-up. 

Results

The majority of patients presented with anterior ST-elevation myocardial infarction(60%) with the left anterior descending artery being the most common target vessel for PPCI followed by right coronary artery (40%). The majority of patients had single vessel disease (60%) on coronary angiography with 15% of patients having underlying diabetes mellitus. Mean left      ventricular function was 41 + 7 % with none in cardiogenic shock. All PPCI was performed by transradial intervention and the use of intracoronary imaging was 75% ( mostly intravascular ultrasound). Thrombus aspiration was performed in 40% of patients and the use of glycoprotein 2b/3a inhibitors was 85%. An average of 1.15 + 0.49 stent were used per patient with mean stent diameter of 3.1 ± 0.4 mm and average length of 28.6 ± 7.2 mm.  At 30-day follow-up, there was no death. There was also no reported reinfarction, TLR and stent thrombosis.   

Conclusion

Our preliminary experience showed that the use of DynamX Bioadaptor DES was feasible in PPCI and there was no reported 30-day MACE.   Longer follow-up in a larger cohort of patients is needed to confirm its long term safety and efficacy.  

Leave Comments